ADO Analysis, page-4202

it really is ADO quintet !!!!!!

assay development - suite of covid tests, sepsis test, as in the webinar, start new rapid test projects

raw materials - supplying ellume, 77e etc for their own tests. vaccine industry with polysaccharides conjugation with anteobind activated Luminex particles. with Serum institute of India being the 1st on board.

assay services - newly formed division with a problem solving perspective leveraging our assay development

battery - cross linked binder, 6 collaborators engaged

battery - silicon anode system, 7 collaborators engaged.

Anteotech has certainly changed in the last 12 months. plenty of future revenue in that lot. imo

also, was thinking about our covid-19 art test. Ellume with a new manufacturing facility is planning to produce 200m tests selling at $30 ea ($6 billion sales?). my initial thinking was Operon producing a max of 8 million test and ellume a couple of million. but if our tests are as good or better than Ellumes, maybe the number of tests we can get produced is a much higher figure, with many more manufactures and licensees. doing some calculations on that is exciting. still plenty of work to be done before we get confirmation of any figures but with a launch date less than 3 months away, the wait shouldn't be that long. imo, dyor, etc...........